Company intelligence / Profile preview

Xenova Ltd.

Reading, Berkshire, United Kingdomorpha.net ↗

Ownership: Private
Development stage: Phase 3

Overview

Xenova developed several clinical programs including a human papillomavirus vaccine (TA-CIN) that reached Phase 2, and addiction vaccines for nicotine and cocaine. Their lead cancer drug tariquidar was discontinued in 2003 due to toxicity concerns. TransMID for brain cancer was projected to potentially reach market by 2007.

Therapeutic areas: PsychiatryOncologyCardiovascular
Modalities: Small molecule drugsTherapeutic vaccinesGenetically engineered subunit vaccines
Industry: Biotech

Drug pipeline

4 assets

transmid

3 more assets in the full pipeline.

Request access →

Partnerships

Celtic Pharma

Beyond the preview

Go deeper on Xenova Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenova Ltd..

Explore the full profile